United States: The New Patent Policy on Natural Products Is a Game Changer for Universities and Life Sciences Companies

Last Updated: September 24 2014
Article by Nicholas J. Landau, Ph.D

Since the 19th Century, it has been considered a given that a person who identifies and purifies a useful natural substance is entitled to a patent, so long as the substance had never before existed in pure form. Due to a new policy enacted by the U.S. Patent and Trademark Office (USPTO), this has recently changed, with serious effects on companies and universities that conduct research in the life sciences. In the view of the USPTO, such inventions can no longer be patented because of the Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 12 (2013). On March 4th of this year, the USPTO issued lengthy guidelines ("the Guidance") to their patent examiners, instructing them to reject any patent claim to a purified natural product.1 From all accounts the examiners have taken this guidance to heart and have been rejecting a wide range of life sciences inventions as a result.

This article explains the contents of the Guidance, their practical effects on the patenting of life science inventions, and possible ways life sciences companies and universities can mitigate their negative impacts.

What Was the Status Quo Ante?

Prior to the Myriad decision, purified natural substances could be patented. The Myriad decision held that isolated DNA that has exactly the same sequence as is found in nature cannot be patented. This created doubt as to whether other purified natural substances had lost their patent-eligible status.

An early example of a patent for a purified natural substance is U.S. Patent 141,072 issued to Louis Pasteur in 1873, which claimed beer yeast "free from organic germs of disease." Likewise, Jokichi Takamine was the first to purify adrenaline, for which he was granted U.S. Patent No. 730,176. Felix Hoffman received U.S. Patent 644,077 in 1898 for purified acetyl salicylic acid, the active ingredient in aspirin.2 Perhaps the best example of a patent for a purified natural substance is Selman Waksman's U.S. Patent 2,449,866 for the landmark antibiotic streptomycin. Waksman's claim 13 reads, in its entirety, "Streptomycin."

Countless additional examples exist. These are some of the most valuable products of the revolution in biology sparked by the discovery in the 19th Century that organisms are composed of chemicals. They include a large fraction of modern drugs and other useful materials.

What Inventions Are Affected?

The Guidance states that it applies to all "natural products" or combinations of natural products. That categorization by itself is unhelpful, as all possible inventions must contain one or more natural products (for example, an aluminum can contains aluminum, a naturally occurring element). The Guidance provides some clarification by providing the following non-exclusive list of materials that fall under the new rules:

  1. Chemicals derived from natural sources (including antibiotics, fats, oils, petroleum derivatives, resins, toxins, etc.)
  2. Foods
  3. Metals and metallic compounds that exist in nature
  4. Minerals
  5. Natural materials (rocks and soil)
  6. Nucleic acids
  7. Organisms (including bacteria, plants, and multicellular animals)
  8. Proteins and peptides
  9. Other substances found in or derived from nature

It should be noted that some categories of materials are limited to those "found in nature" or that "exist in nature," and others are limited to those "derived" from nature. However, others, such as minerals, organisms, nucleic acids, peptides, and proteins, contain no such limitations, and are apparently subject to the new rules regardless of whether they are found in nature or derived from natural sources.

Which Inventions Can Be Patented?

Any invention that involves some "natural product" (including but not limited to those listed above) must comply with new requirements in order to be eligible for patenting. This applies to any invention that includes a natural product as one of its parts, or that uses a natural product in some type of process. It also applies to inventions that do not involve any natural product, but instead involve something that is not "significantly different" from a natural product.

The Guidance proposes a set of 12 factors that must be considered by a patent examiner in determining whether any invention that involves a natural product is eligible for patenting. The goal of the Guidance is to help a patent examiner determine whether a patent claim is "significantly different" from a product of nature. Unfortunately, the subjective nature of the factors and the large number of factors prevent straightforward and predictable analysis.3

More helpful are the five examples of common types of patent claims for natural products given in the Guidance;4 in each of the five examples the Guidance provides a conclusion as to whether the invention is eligible for patenting. These examples are summarized below.

Plasmids are analyzed in Example A. In that example, the Guidance states that a plasmid that is defined only by its function, if that function exists in natural plasmids, cannot be patented. The Guidance also considers whether a bacterium containing two plasmids defined by their functions can be patented. The Guidance concludes that such a bacterium could be patented, so long as natural bacteria do not contain two such plasmids, and the plasmids confer a function that is not found in natural bacteria. The implication of this example is that, if a change to the structure of a naturally occurring thing (such as a bacterium) results in a change in function, this is a significant enough difference to allow it to be patented.

Phytochemicals are considered in Example B. In that example, the Guidance states that a purified form of a natural phytochemical cannot be patented, even if the phytochemical is useful when purified and nearly useless in its natural state. This example states that a modified (methylated) form of a phytochemical can be patented in cases in which the modified form has a function that the natural form does not. The example finally states that a process of treating a disease with the natural phytochemical may be patented, if limited to a specific dosage regimen. The Guidance does not address whether the treatment method could be patented absent the specific dosage regimen. This last question is significant, as it is rare that a working dosage regimen will have been established for a new drug by the time a patent application has been filed.

Examples A and B imply that a change to the structure of a naturally occurring thing resulting in a change in function is a sufficient difference to allow it to be patented.

Fireworks are oddly included in Example C, which does not seem relevant to the life sciences. However, this example states that "gunpowder as recited in the claim [is] not markedly different from what exists in nature." The clear implication is that the USPTO views gunpowder – a mix of various substances made in several ways that never existed prior to its creation by human hands – as a "natural product" that cannot be patented. Merely by including gunpowder in the invention, the "natural product" analysis must be performed. In light of such reasoning, it is difficult to imagine an invention that does not involve a "product of nature" in the eyes of the USPTO, regardless of whether in the final analysis the invention can be patented.

Microbial consortia are the subject of Example D. In this example, a microbial consortium cannot be patented, when all of the species in the consortium are natural, and each species has the same function in the consortium as it does alone. Although the example acknowledges that such a consortium has a wider range of uses than would a single species, it states that because "no species acquires a different use" the consortium is not significantly different from the species in isolation from one another.

In this example, despite a difference in both structure and function between the invention and what is natural, the Guidance concludes that the invention cannot be patented. This example could stand for the proposition that a combination of natural things, in which the function of the whole is no more than the sum of its parts, is not "significantly different" from the things alone. Although the "structure" of the consortium is new, because the species had never lived in consortium in nature, there was no new function as a result.

Polymerase chain reaction (PCR) primers are the subject of Example E, specifically when a pair of primers contains only natural sequences (as is true when primers flank natural genes). The example concludes that a claim for the pair of PCR primers cannot be patented. Both of the primers are isolated versions of naturally occurring sequences, and absent any additional structures or components to distinguish the primers from what occurs naturally, the Guidance finds that the two primers in combination are no more patentable than either would be alone.

In contrast, the Guidance concludes that the process of using the primers in PCR can be patented, for the reason that the specific steps required by PCR (denaturing, polymerizing, renaturing, and providing the proper reagents) limit the use of the primers to a specific artificial application.

This last example is extremely helpful, as it clearly explains that at least one aspect of this common type of biotechnological invention can be patented.

What Should Life Sciences Inventors Do?

Despite the wide-ranging implications of the Guidance, patent applicants should not necessarily forgo attempts to protect their purified natural products or combinations of natural products for the following reasons.

The Guidance May Be Invalidated

The Guidance does not have the force of law. Patent examiners will follow the Guidance, but courts and higher administrative authorities (such as the Patent Trial and Appeals Board, which reviews the examiners' decisions) are not bound by them. The Guidance is a significant departure from the law as it was previously understood and is a significant departure from international standards of patenting. Inevitably it will be challenged in a court of law. The Guidance has received considerable criticism from legal commentators, and it is quite possible that it will be invalidated, in whole or in part, upon such challenge. Consequently, patent applicants should consider maintaining the ability to claim subject matter that might be rejected under the Guidance, in case such a challenge should succeed.

Pay Attention to Foreign Markets

Countries outside of the United States have not shown any interest in following the lead of the USPTO in creating this new exception to patenting. The U.S. and most industrialized countries have signed the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, which allows its participants to exempt only specific types of subject matter from patenting. "Natural products" are not one of the permitted exemptions.5 Although the United States remains the world's largest market in terms of nominal GDP, the European Union (EU) as a whole exceeds the GDP of the U.S. Taken together, the EU, China, and Japan have a GDP that is slightly less than twice that of the United States. Even if the Guidance survives judicial challenges, these foreign markets remain quite lucrative and permit purified natural substances and combinations of natural substances to be patented, so inventors should consider retaining the ability to claim these types of inventions in foreign patents. Based on the increased patenting risk in the U.S., life sciences innovators may also wish to consider shifting the focus of their research to problems that are consequential in major markets outside of the U.S., and away from problems that are unique to the U.S. or primarily of consequence in the U.S.

Consider Trade Secrecy

Patents are not the only form of intellectual property protection available. Certain types of inventions can be protected as trade secrets, and as the U.S. weakens its patent laws, trade secrecy is becoming a more popular form of IP protection. The balance between secrecy and patenting has always been a consideration for innovators in every area of technology, but the Guidance is yet another nudge in the direction of secrecy for life sciences inventions.

For drugs, biologics, and medical devices, trade secrecy is generally impractical, because of the need to obtain regulatory approval from the U.S. Food and Drug Administration.6 For inventions subject to the Guidance that do not require regulatory approval, an analysis should be conducted to determine whether the invention should be maintained as a trade secret.

Before publishing or presenting newly identified genes or other useful natural substances, serious consideration should be given to maintaining any newly discovered natural substance in strict secrecy until its commercial potential can be ascertained, so that patent applications can be filed for all commercially viable, artificially modified forms. In addition, if the substance could be useful in an industry outside of those which have mandated rules of public disclosure, then consideration should be given to maintaining the invention as a permanent trade secret.


[1] The Guidance discusses to a lesser extent inventions that involve "natural principles," but that topic is not within the scope of this article.

[2] Although acetyl salicylic acid is not naturally occurring, it had been made in impure form before Hoffman purified it.

[3] As examples of the subjective nature of the factors, Factor (c) requires a determination of whether the public is "substantially foreclosed from using" the natural product. Factor (g) requires the patent examiner to determine whether elements of the invention are "markedly different in structure." Terms such as "substantially" and "markedly" are intentionally vague, and would be interpreted differently by different people.

[4] The Guidance contains three examples of "laws of nature," which are not discussed here.

[5] TRIPS allows participants to declare that inventions cannot be patented for diagnostic methods, therapeutic methods, surgical methods, plants, animals (but not microorganisms), essentially biological processes for the production of plants or animals, and anything that threatens public order, public morality, human health, animal health, plant health, or the environment. Note that the Guidance specifically states that microorganisms are "natural products," but that TRIPS specifically states that microorganisms are not exempt from patenting.

[6] This is also true to some extent for food additives, cosmetics, dietary supplements, and pesticides, although not in all circumstances.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Foley Hoag LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Foley Hoag LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions